Navigation Links
Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients
Date:5/16/2008

peia's estimates of the market opportunities for PS433540, the implementation of Pharmacopeia's strategic plans, Pharmacopeia's plans to develop PS178990, a product candidate from its SARM program, Pharmacopeia's Phase 1 clinical studies with respect to PS178990, including timing and expected outcomes of such studies, Pharmacopeia's plans to develop PS031291, a product candidate from its chemokine receptor CCR1 program, Pharmacopeia's estimates of the market opportunities for its other product candidates, including PS178990 and PS031291, Pharmacopeia's ability to raise additional capital, Pharmacopeia's anticipated operating results, financial condition, liquidity and capital resources, Pharmacopeia's ability to successfully perform under its collaborations with Bristol-Myers Squibb, Cephalon, GlaxoSmithKline, Schering-Plough and Wyeth, Pharmacopeia's ability to build its pipeline of novel drug candidates through its own internally-funded drug discovery programs, third party collaborations and in-licensing, Pharmacopeia's expectations concerning the development priorities of its collaborators, their ability to successfully develop compounds and its receipt of milestones and royalties from the collaborations, Pharmacopeia's expectations concerning the legal protections afforded by U.S. and international patent law, Pharmacopeia's ability to pursue the development of new compounds and other business matters without infringing the patent rights of others, additional competition, and changes in economic conditions.

Further information about these and other relevant risks and uncertainties may be found in Pharmacopeia's Reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Pharmacopeia urges you to carefully review and consider the disclosures found in its filings which are available in the SEC EDGAR database at http://www.sec.gov and from Pharmacopeia at

SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Pharmacopeia Announces Upcoming Late-Breaker Presentation of Phase 2a Results for Its First-in-Class Investigational DARA Compound, PS433540
2. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
3. Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus
4. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
5. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
6. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
7. Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
8. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
9. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
10. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
11. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014 ResMed (NYSE: RMD ... action against Chinese medical device manufacturer BMC Medical Co., Ltd. ... that BMC,s masks listed below infringe ResMed,s patents, and entered ... masks in the United States : ... mask , Willow nasal pillows mask , iVolve ...
(Date:12/24/2014)... Dec. 23, 2014  Lockton Dunning Benefits, the ... Companies, announced the addition of Vice President ... Lockton Dunning,s Pharmacy Consulting team, Excelsior Solutions. ... industry experience to the position.  Most recently, she ... at Diplomat Specialty Pharmacy, where she has held ...
(Date:12/24/2014)... RALEIGH, N.C. , Dec. 23, 2014 ... plc (NASDAQ: ENDP ) (TSX: ENL), and ... announced today that they have submitted a New Drug ... U.S. Food and Drug Administration (FDA).  Buprenorphine HCl Buccal ... severe enough to require daily, around-the-clock, long-term opioid treatment ...
Breaking Medicine Technology:ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2Kim Foerster Joins Lockton Companies 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5
... June 2 Medarex, Inc.,(Nasdaq: MEDX ... ongoing Phase 1,study of MDX-1106 (ONO-4538: development ... human anti-PD-1 antibody. Data presented from patients ... included the safety,tolerability and pharmacokinetic profile of ...
... presented at the 2008 ASCO Annual Meeting - - Conference call ... ... discuss results -, BRANFORD, Conn., June 1 CuraGen Corporation,(Nasdaq: ... of CR011-vcMMAE for the treatment of unresectable Stage III or,Stage IV melanoma. ...
Cached Medicine Technology:Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting 2Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting 3Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting 4CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma 2CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma 3CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma 4CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma 5CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma 6
(Date:12/24/2014)... (PRWEB) December 24, 2014 Connie Casad, ... and functional medicine advocate with 30 years of practice ... to evaluate the health benefits of dietary detoxification. The ... new participants following excellent results from test patients who ... asked to explain her interest in conducting the study, ...
(Date:12/24/2014)... 24, 2014 The federal court ... the blood thinner caused life-threatening episodes of internal ... structure for the proceeding, Bernstein Liebhard LLP reports. ... Court plans to select lawyers to serve as ... on appointing a Plaintiffs’ Steering Committee, which will ...
(Date:12/24/2014)... 2014 BambooIndustry.com a famous bamboo flooring ... Today, the company announces its multiple layer bamboo ... on these new products. , Bamboo panel is the ... multiple layer bamboo panel board features high quality selective ... emissions free. The bamboo panel consists of multiple layers ...
(Date:12/24/2014)... 2014 (HealthDay News) -- Adults who experienced childhood ... migraine headaches, suggests a study published online Dec. ... "Childhood maltreatment can have long-lasting effects, like associated ... study author Dawn Buse, director of behavioral medicine ... said in a journal news release. "When ...
(Date:12/24/2014)... 24, 2014 Gluten, a protein found ... who have an intolerance to gluten, causing side effects ... migraine headaches, joint pain and fatigue. For this reason, ... that deliver safe and fast weight loss while ... a gluten allergy reaction. These gluten free diet plans ...
Breaking Medicine News(10 mins):Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 3Health News:Bamboo Flooring Company Bambooindustry.com Introduces Its Multiple Layer Bamboo Panel Board Collection 2Health News:Abuse in Childhood Tied to Migraines in Adulthood 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 3
... , PITTSBURGH, Sept. 22 Precision Therapeutics today ... received the Smart Business Magazine 2009 Pacesetters Award. This ... area who are setting the pace for the region. ... of their influence in the community-at-large as well as within ...
... , , ... CutisPharma, Inc. announced the introduction of FIRST(R) - BXN Mouthwash. ... line, which already includes FIRST(R) - Mouthwash BLM. The active ... in the most routinely prepared formulation of Magic Mouthwash containing Benadryl(R), ...
... , , AUSTIN, ... pleased to announce its selection to participate in DEMO conference,s ... features the "coolest, earliest-stage companies." Ringful will launch a mobile ... mobile phone into a connected personal healthcare dashboard, resulting in ...
... Twin ... for 10-city whirlwind tour of Japan to change hearts and minds about the benefits ... , ... (PRWEB) September 22, 2009 -- Twin Triumph Productions, LLC announced today that Academy Award ...
... ATLANTA, Sept. 22 Atlanta Falcons Defensive End Chauncey ... Follmer and Camp Kudzu- Georgia,s largest camp for kids with ... Blank Family Office. , , Davis was ... and Jonathan Babineaux, corporate executives and community leaders during the ...
... research is too focused on new drug development, while not ... advances in knowledge likely to have the biggest impact on ... research policy expert says, adding that a major shift in ... with the coming wave of cancer cases. Professor Richard ...
Cached Medicine News:Health News:Precision Therapeutics President and CEO Sean McDonald Recipient of 2009 Pacesetters Award 2Health News:CutisPharma Launches New Prescription Mouthwash Kit Adding to Product Line 2Health News:Ringful Selected for DEMO's AlphaPitch; Launching PreventiveCare.mobi Healthcare Application Suite 2Health News:Twin Triumph Productions and 'The Power of Two' Go to Japan 2Health News:Twin Triumph Productions and 'The Power of Two' Go to Japan 3Health News:Atlanta Falcons Chauncey Davis Honors 2009 Community Impact Awardees 2Health News:Expert calls for new cancer research priorities 2Health News:Expert calls for new cancer research priorities 3
... The new HF35-50 High Frequency Ultrasound ... high resolution, high frequency system available. The ... ultrasound biomicroscopy of the anterior segment with ... posterior segment ultrasound with a 20 MHz ...
... portable, digital A-scan system which provides easy-to-use ... high frequency, low noise probe and fast ... application of the probe along the visual ... display, storage of 5 different user profiles, ...
... Accurate, efficient and easy to use. The ... variety of regressive, theoretical, and adaptive IOL ... the patient. Convenient design features improve your ... hands-free operation, audible tone to minimize corneal ...
... In addition to three conventional measurement modes ... also incorporates a new axial length measuring ... by calculating sonic velocity for conversion at ... length by calculating each tissues sonic velocity ...
Medicine Products: